A cancer care navigation startup has raised $95 million from prominent tech investors to help payers and providers spend less on cancer patients while improving their health — including by doling out incentive payments to providers and keeping a cut of insurers’ savings.
Thyme Care’s Series C round included new investor Concord Health Partners, and repeat investors such as Town Hall Ventures, Andreessen Horowitz, Foresite Capital and CVS Health Ventures, the company told STAT exclusively. This follows its $60 million Series B, raised just about a year ago, bringing total funds to $178 million.
The size and timing of the deal suggest investors, increasingly focused on financial viability, see vast opportunity in cancer care, which, by some estimates, costs Americans hundreds of billions of dollars a year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect